Upper gastrointestinal bleeding secondary prevention

Revision as of 15:55, 6 November 2017 by Aditya Ganti (talk | contribs) (→‎Overview)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Upper gastrointestinal bleeding Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Upper Gastrointestinal Bleeding from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Management

Initial resuscitation
Pharmacotherapy
Risk stratification

Surgery

Surgical Management
Endoscopic Intervention

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines for Management

Case Studies

Case #1

Upper gastrointestinal bleeding secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Upper gastrointestinal bleeding secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Upper gastrointestinal bleeding secondary prevention

CDC on Upper gastrointestinal bleeding secondary prevention

Upper gastrointestinal bleeding secondary prevention in the news

Blogs on Upper gastrointestinal bleeding secondary prevention

Directions to Hospitals Treating Upper gastrointestinal bleeding

Risk calculators and risk factors for Upper gastrointestinal bleeding secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Effective measures for the secondary prevention of UGIB include discouraging the use of NSAIDS in all patients with a history of UGIB. For patients who are at high risk for rebleeding (elderly patients; those taking anticoagulant and antiplatelet medications), indefinite use of a PPI may be recommended. A combination of nonselective β-blockers plus EVL is the best option for secondary prophylaxis of UGIB from varices.

Secondary prevention

Effective measures for the secondary prevention of UGIB include discouraging the use of NSAIDS in all patients with a history of UGIB.[1]

UGIB from peptic ulcer disease

UGIB from varices

  • A combination of nonselective β-blockers plus EVL is the best option for secondary prophylaxis of UGIB from varices.
  • The nonselective β-blocker should be titrated up as tolerated.
  • Variceal banding should be repeated every 2 to 3 weeks until the varices are obliterated.
    • EGD must be performed 1 to 3 months after initial obliteration then every 6 to 12 months to check for variceal recurrence.

References

  1. Chan FK (2012). "Anti-platelet therapy and managing ulcer risk". J. Gastroenterol. Hepatol. 27 (2): 195–9. doi:10.1111/j.1440-1746.2011.07029.x. PMID 22142030.
  2. Garcia-Tsao, Guadalupe; Sanyal, Arun J.; Grace, Norman D.; Carey, William D. (2007). "Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis". The American Journal of Gastroenterology. 102 (9): 2086–2102. doi:10.1111/j.1572-0241.2007.01481.x. ISSN 0002-9270.



Template:WikiDoc Sources